Background {#Sec1}
==========

There is evidence from both community and clinical studies that social anxiety disorder (SAD), previously termed social phobia, is a prevalent and disabling disorder. In the National Comorbidity Survey (NCS) and National Comorbidity Survey Replication (NCS-R), SAD was one of the most common of all mental disorders (with lifetime prevalence estimates of 16% and 12.1% respectively) \[[@CR1], [@CR2]\]. In each of these surveys, SAD age of onset was early, comorbidity with other mental disorders was high, and subsequent impairment was notable \[[@CR3], [@CR4]\]. Research in clinical settings has also indicated that SAD is a prevalent and disabling condition in this context \[[@CR5], [@CR6]\]. Such data have been key in suggesting the clinical and public health relevance of SAD.

Nevertheless, most of the available data on the epidemiology of SAD originate from high income countries in the West. European epidemiological data have largely been consistent with US data, emphasizing the high prevalence, comorbidity, and morbidity of SAD \[[@CR7]\]. A study using the Diagnostic Interview Schedule in four countries (USA, Canada, Korea, and Puerto Rico) found some consistent patterns, including higher rates in females and considerable comorbidity \[[@CR8]\]. Still, many questions about the cross-national epidemiology of SAD remain unanswered. It has been suggested, for example, that anxiety disorders such as SAD are a peculiarly Western construct (in the East, for example, there may be more concern with offending others than with embarrassing oneself) \[[@CR9]\]; from this perspective it might be hypothesized that SAD is less prevalent elsewhere, or that thresholds for SAD diagnosis differ across the globe.

Few data have systematically addressed the 30-day prevalence of SAD (which is important in establishing the prevalence at a particular point in time), whether age of onset and persistence vary across a range of different countries, whether impairment associated with SAD differs from place to place, and whether SAD treatment differs across the globe. Data on socio-demographic correlates of SAD and on comorbidity with other mental disorders have again mainly been reported in high income Western contexts. The WHO World Mental Health (WMH) Survey Initiative provides an important opportunity to investigate the epidemiology of SAD across a range of countries. In the current study, we assessed 30-day, 12-month, and lifetime SAD prevalence; age of onset; persistence; severity of role impairment associated with SAD; and treatment of SAD, across countries. In addition we investigated socio-demographic correlates of SAD, and comorbidity of SAD with other mental disorders, in the combined sample.

Methods {#Sec2}
=======

Samples {#Sec3}
-------

Interviews were administered in 13 regions classified by the World Bank \[[@CR10]\] as high income (Australia, Belgium, France, Germany, Italy, Japan, New Zealand, Northern Ireland, Poland, Portugal, Spain, The Netherlands, USA), seven as upper-middle income (Brazil, Bulgaria, Colombia-Medellin, Lebanon, Mexico, Romania, South Africa), and six as low/lower-middle income (Colombia, Iraq, Nigeria, Peru, People's Republic of China \[PRC\], Ukraine). Classified by region, surveys are from Africa (Nigeria, South Africa), the Americas (Brazil, Colombia, Mexico, Peru, USA), Eastern Europe (Bulgaria, Poland, Romania, Ukraine), Western Europe (Belgium, France, Germany, Italy, Northern Ireland, Portugal, Spain, The Netherlands), Western Pacific (Australia, Japan, New Zealand, PRC), and Eastern Mediterranean (Iraq, Lebanon).

All but ten surveys were based on area probability household samples representative of the entire nation (see Table [1](#Tab1){ref-type="table"} for survey details). The exceptions were surveys of all urbanized areas in three countries (Colombia, Mexico, Peru), of a specific region in two countries (Colombia-Medellin, Spain-Murcia), of specific metropolitan areas in three countries (São Paulo in Brazil; a series of cities in Japan; Beijing, Shanghai and Shen Zhen in PRC) and of selected states in one country (Nigeria). Respondents had to be at least 18 years of age in most countries (20 in Japan). Five surveys (Colombia, Colombia-Medellin, Mexico, Peru, Poland) had an upper age limit (64 or 65), and one (Australia) had an upper age limit of 85.Table 1World Mental Health sample characteristics by World Bank income categoriesCountrySurveySample characteristicsField datesAge range^b^Sample sizeResponse rate (%)Part 1Part 2 subsampleLow/lower-middle income countries^a^ColombiaNSMHAll urban areas of the country (approximately 73% of the total national population)200318--654426238187.7IraqIMHSNationally representative2006--200718+4332433295.2NigeriaNSMHW21 of the 36 states in the country, representing 57% of the national population. The surveys were conducted in Yoruba, Igbo, Hausa and Efik languages2002--200318+6752214379.3PeruEMSMPFive urban areas of the country (approximately 38% of the total national population)2004--200518--653930180190.2PRC Beijing/ShanghaiB-WMH S-WMHBeijing and Shanghai metropolitan areas2002--200318+5201162874.7PRC Shen ZhenShenzhenShen Zhen metropolitan area. Included temporary residents as well as household residents2006--200718+7132247580.0UkraineCMDPSDNationally representative200218+4725172078.3Upper-middle income countries^a^BrazilSão Paulo MegacitySão Paulo metropolitan area2005--200718+5037294281.3BulgariaNSHSNationally representative2003--200718+5318223372.0Colombia (Medellin)^c^MMHHSMedellin metropolitan area2011--201218--653261167397.2LebanonLEBANONNationally representative2002--200318+2857103170.0MexicoM-NCSAll urban areas of the country (approximately 75% of the total national population)2001--200218--655782236276.6RomaniaRMHSNationally representative2005--200618+2357235770.9South AfricaSASHNationally representative2003--200418+4315431587.1High income countries^a^AustraliaSMHWBNationally representative200718--858463846360.0BelgiumESEMeDNationally representative2001--200218+2419104350.6FranceESEMeDNationally representative2001--200218+2894143645.9GermanyESEMeDNationally representative2002--200318+3555132357.8ItalyESEMeDNationally representative2001--200218+4712177971.3JapanWMHJEleven metropolitan areas2002--200620+4129168255.1New ZealandNZMHSNationally representative2003--200418+12790731273.3Northern IrelandNISHSNationally representative2004--200718+4340198668.4PolandEZOPNationally representative2010--201118--6410081400050.4PortugalNMHSNationally representative2008--200918+3849206057.3SpainESEMeDNationally representative2001--200218+5473212178.6Spain (Murcia)PEGASUS-MurciaMurcia region2010--201218+2621145967.4The NetherlandsESEMeDNationally representative2002--200318+2372109456.4USANCS-RNationally representative2002--200318+9282569270.9Total142,40574,843Weighted average response rate (%)69.4^a^The World Bank. (2008). Data and Statistics. Accessed May 12, 2009 at: <http://go.worldbank.org/D7SN0B8YU0>^b^For the purposes of cross-national comparisons we limit the sample to those 18+^c^The newer Colombian survey in Medellin classified Colombia as an upper-middle income country (due to a change of classification by the World Bank), although in the original survey Colombia was classified as a low/lower-middle income countryESEMeD (The European Study Of The Epidemiology Of Mental Disorders); NHS (Israel National Health Survey); WMHJ 2002-2006 (World Mental Health Japan Survey); NZMHS (New Zealand Mental Health Survey); NCS-R (The USA National Comorbidity Survey Replication); NSMH (The Colombian National Study of Mental Health); WMHI (World Mental Health India); LEBANON (Lebanese Evaluation of the Burden of Ailments and Needs of the Nation); M-NCS (The Mexico National Comorbidity Survey); SASH (South Africa Stress and Health Study); CMDPSD (Comorbid Mental Disorders during Periods of Social Disruption)

Interviews were conducted face to face in respondent homes after obtaining informed consent. Human Subjects Committees monitored the surveys and approved recruitment and consent procedures in each country. Other than in Australia, Iraq, Romania, and South Africa, where all respondents were administered the full interview, internal subsampling was used to reduce respondent burden by dividing the interview into two parts. Part 1 assessed core disorders, including SAD, and was administered to all respondents. Part 2 included additional disorders and correlates and was administered to all Part 1 respondents who met criteria for any lifetime Part 1 disorder plus a probability subsample of other respondents. Part 1 data were weighted to adjust for differential probabilities of selection and to match population distributions on census socio-demographic and geographic distributions. Part 2 data were additionally weighted for the under-sampling of Part 1 respondents without core disorders. Response rates range from a low of 45.9% (France) to 97.2% (Colombia-Medellin) (69.4% weighted average) (Table [1](#Tab1){ref-type="table"}). Technical details about WMH sample design are presented elsewhere \[[@CR11]\].

Measures {#Sec4}
--------

The WMH interviews assess prevalence and a wide range of predictors and consequences of numerous anxiety, mood, impulse control, and substance use disorders \[[@CR12]\]. The full text of the interview schedule is available at [www.hcp.med.harvard.edu/wmh](http://www.hcp.med.harvard.edu/wmh). The WMH interview schedule was developed in English and translated into other languages using a standardized WHO translation, back-translation, and harmonization protocol described elsewhere \[[@CR13]\]. Consistent interviewer training and quality control monitoring procedures were used in all surveys to facilitate cross-national comparison \[[@CR14]\]. The following sections emphasize the measures considered in the current report.

### Mental disorders {#Sec5}

SAD and other Diagnostic and Statistical Manual of Mental Disorders (DSM)-IV anxiety (i.e., panic disorder with or without agoraphobia, agoraphobia without panic disorder, generalized anxiety disorder, specific phobia, post traumatic stress disorder, and separation anxiety disorder), mood (i.e., major depressive episode, bipolar disorder), impulse control (i.e., intermittent explosive disorder, bulimia nervosa, binge eating disorder, oppositional defiant disorder, conduct disorder, attention deficit disorder), and substance use disorders (i.e., alcohol abuse and drug abuse with or without dependence) were assessed using Version 3.0 of the WHO Composite International Diagnostic Interview (CIDI 3.0) \[[@CR15]\], a fully structured lay-administered interview. Respondents were administered the full SAD section if they endorsed a diagnostic stem question for one or more performance or interactional fears described as excessive and causing substantial distress or avoidance. The SAD section screened for lifetime experiences of shyness, fear, and discomfort associated with each of 14 social situations. Respondents endorsing one or more such questions were asked about all DSM-IV criteria. Age of onset (AOO) of each disorder was assessed using special probing techniques shown experimentally to improve recall accuracy \[[@CR16]\]. CIDI diagnoses were compared to blinded clinical diagnoses using the Structured Clinical Interview for DSM-IV (SCID) \[[@CR17]\] in probability subsamples of WMH respondents from France, Italy, Spain, and the USA. As detailed elsewhere, good CIDI-SCID diagnostic concordance was found for SAD --- area under the curve (AUC) = 0.67 --- and most other DSM-IV/CIDI disorders \[[@CR18]\].

### Impairment {#Sec6}

The Sheehan Disability Scale (SDS) \[[@CR19]\] was used to assess recent impairment in role functioning in each of four domains (home, work, relationship, and social) in respondents with a 12-month SAD diagnosis. The response scale is from 0 to 10, with severe impairment in a specific role domain defined as a score ≥7. In addition, respondents were asked how many days in the past year they were unable to work or carry out their normal activities due to their disorder (days out of role).

### Treatment {#Sec7}

The 12-month treatment was assessed by asking respondents if they had seen any of a list of professionals for problems with emotions, nerves, mental health, or alcohol or drug use, including both inpatient and outpatient care. Sectors included were as follows: specialty mental health (e.g., psychiatrist and non-psychiatrist mental health specialist), general medical (e.g., general practitioner), human services sector (e.g., religious advisor), and complementary and alternative medicine (e.g., herbalist or homeopath).

### Demographic factors {#Sec8}

We examined age (18--29, 30--44, 45--59, 60+), time since onset, gender, employment status (student, homemaker, retired, other, employed), marital status (never married, divorced/separated/widowed, currently married), education level (no education, some primary, finished primary, some secondary, finished secondary, some college, finished college), and household income (low, low average, high average, and high, which were based on country-specific quartiles of gross household earnings in the past 12 months) \[[@CR20]\].

Statistical analysis {#Sec9}
--------------------

Cross-tabulations were used to calculate prevalence, impairment, comorbidity, and treatment. Significance was calculated using Wald and McNemar's chi-square tests. Survival analysis was used to estimate AOO and projected lifetime risk, as the young age of many respondents biases the AOO distribution downwards. The actuarial method implemented in SAS 9.4 (PROC LIFETEST) was used to generate the AOO curves. Logistic regression and survival analyses were used to examine socio-demographic correlates. Because the data were weighted and clustered, the Taylor series linearization method \[[@CR21]\] implemented in the SUDAAN software package 11.0 \[[@CR22]\] was used to estimate design-based standard errors. Statistical significance was consistently evaluated using two-sided tests, with *P* \< 0.05 considered significant.

Results {#Sec10}
=======

Prevalence {#Sec11}
----------

On average, the estimated lifetime, 12-month, and 30-day prevalence is highest in high income countries (5.5%, 3.1%, 1.7%), intermediate in upper-middle income countries (2.9%, 2.1%, 1.3%), and lowest in low/lower-middle income countries (1.6%, 1.0%, 0.5%) (Table [2](#Tab2){ref-type="table"}). Prevalence rates are highest in the Americas and the Western Pacific region, and lowest in Africa and the Eastern Mediterranean. Across all countries, SAD is a prevalent disorder (4.0%, 2.4%, 1.3%). Comparison of lifetime, 12-month, and 30-day prevalence across all countries, across different income groups, and across different regional groups all reached significance (*P* \< 0.001) (Table [2](#Tab2){ref-type="table"}).Table 2Prevalence of DSM-IV social anxiety disorder (SAD) in the World Mental Health surveysCountryLifetime prevalence12-month prevalence30-day prevalence12-month prevalence of SAD among lifetime cases30-day prevalence of SAD among 12-month casesSample size used%SE%SE%SE%SE%SELow/lower-middle income countries1.60.11.00.10.50.062.62.552.03.436,498 Colombia5.00.52.90.31.60.358.04.654.96.14426 Iraq0.80.20.70.20.50.286.07.572.06.94332 Nigeria0.20.10.20.10.10.196.33.983.311.76752 Peru2.60.31.40.10.50.154.23.235.56.83930 PRC China0.50.10.40.10.20.166.611.952.813.75201 PRC Shen Zhen0.90.20.70.10.20.176.56.029.39.97132 Ukraine2.60.21.50.21.00.259.94.962.37.84725Upper-middle income countries2.90.12.10.11.30.172.42.161.42.628,927 Brazil5.60.43.90.32.70.370.84.567.55.25037 Bulgaria0.80.20.60.20.40.174.77.058.99.45318 Colombia (Medellin)4.60.53.80.52.20.482.73.858.36.53261 Lebanon1.90.41.30.30.80.267.07.061.39.42857 Mexico2.90.22.00.21.10.269.44.053.44.95782 Romania1.30.31.00.20.60.274.78.360.112.22357 South Africa2.80.41.90.31.20.268.75.864.45.64315High income countries5.50.13.10.11.70.157.31.053.11.276,980 Australia8.50.44.20.31.90.249.82.944.73.38463 Belgium2.00.41.20.20.70.259.87.258.413.52419 France4.30.52.60.41.80.359.35.271.86.72894 Germany2.50.31.50.21.00.260.46.063.77.73555 Italy1.90.21.10.20.60.160.05.452.88.64712 Japan1.40.20.70.20.50.151.98.168.49.34129 New Zealand9.50.35.30.32.80.256.01.852.52.512,790 Northern Ireland6.00.44.00.32.50.365.82.963.44.64340 Poland1.40.10.90.10.50.163.43.855.14.510,081 Portugal4.70.53.10.41.70.267.13.954.24.83849 Spain1.20.20.70.10.40.156.36.958.612.45473 Spain (Murcia)1.70.21.20.20.90.267.711.074.410.32621 The Netherlands2.60.41.30.31.00.350.89.373.98.12372 USA12.10.47.10.33.50.258.81.748.91.99282All countries combined4.00.12.40.11.30.060.20.854.51.0142,405WHO regions^a^ Region of the Americas6.40.24.00.12.10.162.81.353.11.631,718 African region1.20.20.90.10.60.171.15.566.75.311,067 Western Pacific region5.50.23.00.11.50.154.51.549.41.937,715 Eastern Mediterranean region1.20.20.90.20.60.174.25.766.06.17189 Western European region3.00.11.90.11.20.162.41.862.32.532,235 Eastern European region1.50.11.00.10.60.164.72.758.63.722,481Comparison between countries^b^χ^2^ ~27~ = 78.6\*, *P* \< 0.001χ^2^ ~27~ = 46.3\*, *P* \< 0.001χ^2^ ~27~ = 25.7\*, *P* \< 0.001χ^2^ ~27~ = 3.3\*, *P* \< 0.001χ^2^ ~27~ = 2.4\*, *P* \< 0.001Comparison between low, middle, and high income country groups^b^χ^2^ ~2~ = 387.5\*, *P* \< 0.001χ^2^ ~2~ = 224.2\*, *P* \< 0.001χ^2^ ~2~ = 121.7\*, *P* \< 0.001χ^2^ ~2~ = 21.3\*, *P* \< 0.001χ^2^ ~2~ = 4.5\*, *P* = 0.01Comparison between WHO regions^b^χ^2^ ~5~ = 207.5\*, *P* \< 0.001χ^2^ ~5~ = 118.4\*, *P* \< 0.001χ^2^ ~5~ = 53.2\*, *P* \< 0.001χ^2^ ~5~ = 6.1\*, *P* \< 0.001χ^2^ ~5~ = 5.2\*, *P* \< 0.001\*Significant at the 0.05 level^a^ *Region of the Americas* (Colombia, Mexico, Brazil, Peru, USA, Medellin); *African region* (Nigeria, South Africa); *Western Pacific region* (PRC Shen Zhen, PRC Beijing and Shanghai, Japan, Australia, New Zealand); *Eastern Mediterranean region* (Iraq, Lebanon); *Western European region* (Belgium, France, Germany, Italy, The Netherlands, Spain, Northern Ireland, Portugal, Murcia); *Eastern European region* (Romania, Bulgaria, Poland, Ukraine)^b^Chi-square test of homogeneity to determine if there is variation in prevalence estimates across countries*SE* standard error

The ratio of the 12-month prevalence to lifetime prevalence is an indirect indicator of disorder persistence. This ratio is lowest in high income countries (57.3%) and the Western Pacific (54.5%), and highest in upper-middle income countries (72.4%), Africa (71.1%), and the Eastern Mediterranean (74.2%). Across all countries, SAD is a persistent disorder (60.2%). The ratio of the 30-day prevalence to 12-month prevalence is an indirect indicator of episode persistence among those with recent disorder. This ratio is again lowest in the Western Pacific (49.4%), and highest in upper-middle income countries (61.4%), Africa (66.7%), and the Eastern Mediterranean (66.0%). Comparison of disorder and episode persistence across all countries, across different income groups, and across different regional groups all reached significance (*P* \< 0.001) (Table [2](#Tab2){ref-type="table"}).

Age of onset {#Sec12}
------------

Table [3](#Tab3){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"} indicate that the median estimated AOO is similar for high income, upper-middle income, and low/lower-middle income countries. Across all countries, the risk period for onset of SAD ranges from the mid-late adolescence to the early 40s. In high income countries, the earliest median AOO estimates occurr in Poland (50% by age 11), whereas the latest are in The Netherlands (50% by age 17). In upper-middle countries, the earliest median AOO estimates are in Colombia (50% by age 13), and the latest in South Africa (50% by age 26). In low/lower-middle income countries, the earliest median AOO estimates are in Nigeria (50% by age 11), and the latest in Peru (50% by age 16). Projected lifetime risk for SAD across the globe is 4.4%.Table 3Age at selected percentiles on the standardized age of onset distributions of DSM-IV SAD with projected lifetime risk at age 75CountryAges at selected percentilesLifetime prevalence of SADProjected risk at age 75510255075909599%SE%SELow/lower-middle income countries781115192636571.60.11.70.1 Colombia^a^681115192631395.00.55.30.5 Iraq791314182336360.80.20.80.2 Nigeria77711192324240.20.10.20.1 Peru^a^9101316192734412.60.32.70.3 PRC China8121414171937370.50.10.50.1 PRC Shen Zhen571114182631410.90.21.00.2 Ukraine781114162537572.60.22.90.3Upper-middle income countries571115203649672.90.13.40.2 Brazil571114172941545.60.46.10.4 Bulgaria881114182431380.80.20.90.2 Colombia (Medellin)^a^55813162131414.60.54.70.5 Lebanon671114182026301.90.42.00.4 Mexico^a^671115192640542.90.23.20.3 Romania10131421365858581.30.31.80.4 South Africa11131626496767672.80.44.71.2High income countries56913172942594.00.16.00.1 Australia56914203746688.50.49.60.5 Belgium55713172536362.00.42.20.4 France781114203145574.30.54.90.5 Germany791114355062622.50.33.00.5 Italy571315202836561.90.22.00.3 Japan55913162943481.40.21.60.2 New Zealand56813172738579.50.310.40.4 Northern Ireland561014204049546.00.47.10.5 Poland^b^55811141719211.40.11.40.1 Portugal55914182943614.70.55.20.5 Spain55913192248481.20.21.30.2 Spain (Murcia)55513183337401.70.21.90.3 The Netherlands571117294149522.60.43.10.5 USA568131523325112.10.413.00.5All countries combined56914183144624.00.14.40.1WHO regions Region of the Americas56913172636526.40.26.90.2 African region7131523476767671.20.22.00.5 Western Pacific region56914183346665.50.26.10.2 Eastern Mediterranean region681114182326361.20.21.30.2 Western European region561014203645613.00.13.40.1 Eastern European region57913172438581.50.11.70.1^a^The projected risk for these countries is at age 65 because the age range of these surveys is between 18--65^b^The projected risk for this country is at age 64 because the age range of this survey is between 18--64*SE* standard error Fig. 1Age of onset of SAD by country income level

Impairment {#Sec13}
----------

SAD is associated with substantial impairment in multiple domains of role functioning in the WMH data (Table [4](#Tab4){ref-type="table"}) and with a mean number of days out of work of 24.7 (1.8) in the past year ([Appendix 1](#Sec20){ref-type="sec"}: Table 8). However, in most countries, the proportion of respondents with 12-month SAD and severe role impairment (SDS score of 7--10) is higher in the domains of relationships and social situations than in the domains of home and work. Furthermore, in most countries, between one-third and one-half of respondents with 12-month SAD have severe role impairment in at least one domain. Notably, there are no significant differences between low, middle, and high income groups, or between different WHO regions, in the proportion of respondents with severe role impairment in at least one domain.Table 4Severity of role impairment (Sheehan Disability Scale: SDS) associated with 12-month SAD, by countryCountryProportion with severe role impairment (SDS score: 7--10)Number of 12-month casesHomeWorkRelationshipSocialAny^a^%SE%SE%SE%SE%SELow/lower-middle income countries^c,d,e,g^9.31.614.12.418.02.621.22.834.33.2349 Colombia^c,d,e,g,h^8.12.318.15.222.54.932.35.043.25.3133 Iraq^f^18.09.29.05.431.612.722.78.348.012.628 Nigeria7.87.828.215.724.113.924.113.936.317.49 Peru13.74.713.45.211.74.020.67.733.07.951 PRC China4.94.84.64.64.64.617.412.126.913.016 PRC Shen Zhen2.11.91.41.21.21.26.13.59.44.245 Ukraine^d,h^11.54.118.45.623.15.812.24.733.06.467Upper-middle income countries^c,d,e,f,g^12.71.817.02.528.52.228.52.239.32.6601 Brazil^c,d,e,g^13.94.020.56.125.83.527.73.936.74.7186 Bulgaria^d,f^5.32.92.51.023.211.010.04.725.810.827 Colombia (Medellin)^c,d,e,f,g^12.54.019.84.633.56.133.66.043.26.1110 Lebanon^d,e,f,g^14.16.47.95.543.710.033.89.845.89.635 Mexico^d,e,f,g^7.32.011.93.223.43.728.14.235.24.4134 Romania26.010.931.511.940.412.932.011.056.29.822 South Africa^d^16.65.217.96.027.46.128.15.943.68.187High income countries^c,d,e,f,g,h^11.00.716.80.823.61.029.81.137.71.12510 Australia^c,d,e,f,g,h^17.22.724.32.837.23.943.14.250.14.0381 Belgium^c,d,e^9.66.928.110.737.013.138.48.854.98.328 France^e,g^9.95.111.04.317.54.024.05.332.95.972 Germany^c,d,e,g^4.03.014.14.920.05.928.07.942.27.958 Italy^f^15.96.17.93.923.36.017.16.333.16.953 Japan^c,d^6.55.926.28.320.48.025.79.437.88.825 New Zealand^c,d,e,f,g,h^6.11.112.31.318.81.926.72.132.52.1720 Northern Ireland^d,e,g,h^19.62.724.73.031.43.441.44.352.34.1183 Poland14.24.621.34.818.64.521.45.232.45.691 Portugal^c,d,e,g^7.22.113.42.515.82.719.43.225.13.9124 Spain8.25.415.67.321.29.817.08.226.310.533 Spain (Murcia)^c,d,e,f,g^25.88.941.712.767.211.062.46.871.69.433 The Netherlands^c^41.911.256.812.746.813.956.111.163.612.030 USA^c,d,e,f,g,h^10.91.315.41.422.61.628.81.436.51.7679All countries combined^c,d,e,f,g,h^11.10.716.50.823.90.928.60.937.61.03460WHO regions Region of the Americas^c,d,e,f,g,h^11.01.016.51.423.71.329.01.337.51.51293 African Region^d,e^15.64.719.15.627.05.627.65.442.77.496 Western Pacific region^c,d,e,f,g,h^8.11.014.21.121.41.628.71.834.91.81187 Eastern Mediterranean Region^d,e,f,g^15.85.48.43.938.47.928.97.046.87.763 Western European Region^c,d,e,f,g,h^14.41.720.22.026.72.031.42.241.72.4614 Eastern European Region^c,d,h^13.22.618.33.123.43.617.63.134.23.7207Comparison between countries^b^χ^2^ ~27~ = 2.3\*, *P* \< 0.001χ^2^ ~27~ = 2.9\*, *P* \< 0.001χ^2^ ~27~ = 3.0\*, *P* \< 0.001χ^2^ ~27~ = 2.8\*, *P* \< 0.001χ^2^ ~27~ = 2.6\*, *P* \< 0.001Comparison between low, middle, and high income country groups^b^χ^2^ ~2~ = 1.0, *P* = 0.371χ^2^ ~2~ = 0.6, *P* = 0.561χ^2^ ~2~ = 4.7\*, *P* = 0.008χ^2^ ~2~ = 4.1\*, *P* = 0.016χ^2^ ~2~ = 0.8, *P* = 0.463Comparison between WHO regions^b^χ^2^ ~5~ = 2.9\*, *P* = 0.013χ^2^ ~5~ = 2.3\*, *P* = 0.042χ^2^ ~5~ = 1.5, *P* = 0.180χ^2^ ~5~ = 2.7\*, *P* = 0.020χ^2^ ~5~ = 1.5, *P* = 0.175\*Significant at the 0.05 level^a^Highest severity category across four SDS role domains^b^Chi-square test of homogeneity to determine if there is variation in impairment severity across countries. McNemar's chi-square test to determine if there is a significant difference for ^c^home vs work impairment, ^d^home vs relationship impairment, ^e^home vs social impairment, ^f^work vs relationship impairment, ^g^work vs social impairment, ^h^relationship vs social impairment for each row entry. For example, ^c^for Colombia indicates that the proportion with severe impairment associated with social anxiety disorder is significantly higher for work than home

However, there are significant differences across countries in proportion of 12-month SAD respondents with severe role impairment in any of the domains (ranging from 9.4% in PRC Shen Zhen to 71.6% in Spain-Murcia) (Table [4](#Tab4){ref-type="table"}), and there are also some differences in specific domains across country, income region, and WHO region. The proportion of respondents with severe home impairment varies significantly by country and by WHO region; it is lowest in PRC Shen Zhen (2.1%) and the Western Pacific (8.1%), and highest in The Netherlands (41.9%) and the Eastern Mediterranean (15.8%). The proportion of respondents with severe work impairment varies significantly by country and by WHO region; it is lowest in the PRC Shen Zhen (1.4%) and the Eastern Mediterranean (8.4%), and highest in the Netherlands (56.8%) and Western Europe (20.2%). The proportion of respondents with severe relationship impairment varies significantly by country and by income region (lowest in low/lower-middle income countries, i.e., 18%, and highest in upper-middle income countries, i.e., 28.5%). The proportion of respondents with severe social impairment varies by country, by WHO region (lowest in Eastern Europe, i.e., 17.6%, highest in Western Europe, i.e., 31.4%), and by income region (lowest in low/lower-middle income, i.e., 21.2%, highest in high income, i.e., 29.8%).

Socio-demographic correlates {#Sec14}
----------------------------

Table [5](#Tab5){ref-type="table"} shows the bivariate associations of the socio-demographic characteristics with SAD in the combined sample. Both 30-day and lifetime risk of SAD are associated with younger AOO, female gender, not being employed, being unmarried (never married or divorced/widowed/separated), lower educational status, and low household income. SAD recurrence (as indicated by 12-month SAD in lifetime cases) is associated with female gender, earlier AOO, and being unmarried --- while persistence (as indicated by 30-day SAD in 12-month cases) is associated with female gender but not with earlier AOO or marital status. SAD recurrence is particularly highly associated with lower education (with no education having an odds ratio \[OR\] of 5.6, confidence interval \[CI\] 2.2--14.4), SAD persistence is particularly associated with being a student (OR of 2.1, CI 1.4--3.0), and both recurrence and persistence are associated with being a homemaker. Socio-demographic correlates are similar across countries for the most part, but also demonstrate some differences ([Appendix 2](#Sec21){ref-type="sec"}: Table 9, [Appendix 3](#Sec22){ref-type="sec"}: Table 10, and [Appendix 4](#Sec22){ref-type="sec"}: Table 11).Table 5Bivariate associations between socio-demographics correlates and DSM-IV social anxiety disorder (all countries combined)Correlates30-day Social Anxiety Disorder^a^Lifetime Social Anxiety Disorder^b^12-month Social Anxiety Disorder among lifetime cases^c^30-day Social Anxiety Disorder among 12-month cases^c^OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)Age-cohort 18-293.2\*(2.6-3.9)3.6\*(3.2-4.0) 30-442.8\*(2.3-3.4)2.9\*(2.6-3.2) 45-592.5\*(2.0-3.1)2.4\*(2.1-2.6) 60+1.01.0Age-cohort difference^d^χ^2^ ~3~ = 145.4\*, *P* \< .001χ^2^ ~3~ = 547.3\*, *P* \< .001Age of onset Early1.5\*(1.2-1.8)1.0(0.7-1.2) Early-average1.4\*(1.1-1.7)0.9(0.7-1.2) Late-average1.1(0.9-1.3)0.9(0.8-1.2) Late1.01.0Age of onset difference^d^χ^2^ ~3~ = 15.4\*, *P* = 0.002χ^2^ ~3~ = 0.5, *P* = 0.926Time since onset (Continuous)0.98\*(0.98-0.99)1.01\*(1.00-1.01)χ^2^ ~1~ = 63.1\*, *P* \< .001χ^2^ ~1~ = 5.0\*, *P* = 0.025Gender Female1.7\*(1.5-1.9)1.3\*(1.2-1.4)1.3\*(1.2-1.5)1.2\*(1.0-1.4) Male1.01.01.01.0Gender difference^d^χ^2^ ~1~ = 65.3\*, *P* \< .001χ^2^ ~1~ = 61.5\*, *P* \< .001χ^2^ ~1~ = 15.7\*, *P* \< .001χ^2^ ~1~ = 5.9\*, *P* = 0.015Employment status Student1.4\*(1.1-1.9)1.2(1.0-1.4)1.1(0.8-1.6)2.1\*(1.4-3.0) Homemaker1.5\*(1.3-1.7)1.2\*(1.1-1.3)1.4\*(1.1-1.7)1.4\*(1.1-1.8) Retired0.6\*(0.5-0.8)0.9(0.7-1.0)1.0(0.7-1.3)0.9(0.6-1.3) Other1.8\*(1.5-2.1)1.5\*(1.3-1.6)2.0\*(1.6-2.6)1.0(0.8-1.3) Employed1.01.01.01.0Employment status difference^d^χ^2^ ~4~ = 81.8\*, *P* \< .001χ^2^ ~4~ = 63.6\*, *P* \< .001χ^2^ ~4~ = 36.9\*, *P* \< .001χ^2^ ~4~ = 20.4\*, *P* \< .001Marital status Never married1.2\*(1.1-1.4)1.4\*(1.3-1.5)1.3\*(1.1-1.6)1.0(0.8-1.2) Divorced/separated/widowed1.5\*(1.3-1.7)1.3\*(1.2-1.5)1.4\*(1.1-1.6)1.0(0.8-1.3) Currently married1.01.01.01.0Marital status difference^d^χ^2^ ~2~ = 26.6\*, *P* \< .001χ^2^ ~2~ = 75.7\*, *P* \< .001χ^2^ ~2~ = 18.4\*, *P* \< .001χ^2^ ~2~ = 0.2, *P* = 0.887Education level No education1.3(0.8-2.2)0.8(0.6-1.2)5.6\*(2.2-14.4)1.2(0.6-2.6) Some primary1.8\*(1.3-2.4)1.1(0.9-1.3)3.0\*(2.1-4.3)1.7\*(1.1-2.8) Finished primary1.5\*(1.2-2.0)1.2(1.0-1.4)2.0\*(1.4-2.8)1.1(0.7-1.8) Some secondary1.4\*(1.1-1.7)1.2\*(1.1-1.3)1.6\*(1.3-2.0)1.0(0.8-1.4) Finished secondary1.0(0.8-1.2)1.1(1.0-1.2)1.3\*(1.1-1.6)0.8(0.6-1.0) Some college1.0(0.8-1.2)1.1(1.0-1.2)1.3\*(1.0-1.6)0.8(0.6-1.0) Finished college1.01.01.01.0Education level difference^d^χ^2^ ~6~ = 33.6\*, *P* \< .001χ^2^ ~6~ = 16.2\*, *P* = 0.013χ^2^ ~6~ = 54.1\*, *P* \< .001χ^2^ ~6~ = 14.8\*, *P* = 0.022Household income Low1.4\*(1.2-1.7)1.1\*(1.0-1.2)1.6\*(1.3-1.9)1.4\*(1.0-1.8) Low-average1.3\*(1.0-1.5)1.0(0.9-1.1)1.4\*(1.1-1.7)1.3(1.0-1.7) High-average1.1(0.9-1.3)1.0(0.9-1.1)1.1(0.9-1.4)1.1(0.9-1.4) High1.01.01.01.0Household income difference^d^χ^2^ ~3~ = 19.4\*, *P* \< .001χ^2^ ~3~ = 10.5\*, *P* = 0.015χ^2^ ~3~ = 23.1\*, *P* \< .001χ^2^ ~3~ = 6.9, *P* = 0.077N^e^142,4056,081,56157583460\*Significant at the .05 level, 2 sided test^a^These estimates are based on logistic regression models adjusted for age, gender and country^b^These estimates are based on survival models adjusted for age-cohorts, gender, person-years and country^c^These estimates are based on logistic regression models adjusted for time since social anxiety disorder onset, age of social anxiety disorder onset, gender and country^d^Chi square test of significant differences between blocks of sociodemographic variables^e^Denominator N: 142,405 = total sample; 6,081,561 = number of person-years in the survival models; 5,758 = number of lifetime cases of social anxiety disorder; 3,460 = number of 12-month social anxiety disorder cases

Comorbidity {#Sec15}
-----------

Table [6](#Tab6){ref-type="table"} shows that respondents with either lifetime or 12-month SAD are most likely to meet lifetime criteria for other anxiety disorders (59.8% and 64.9%), less likely to meet lifetime criteria for mood and substance use disorders, and least likely to meet lifetime criteria for impulse control disorders (19.3% and 21.9%); in both cases around 80% of such respondents meet lifetime criteria for any other mental disorder. Similarly, respondents with 12-month SAD are most likely to meet 12-month criteria for other anxiety disorders (52.7%), less likely to meet 12-month criteria for mood and impulse control disorders, and least likely to meet 12-month criteria for substance use disorders (10.2%); with 66.9% of such respondents meeting 12-month criteria for any other disorder. For both lifetime and 12-month SAD, SAD begins earlier in only 31.4--35.4% of cases of anxiety disorder, but SAD begins earlier in 48.8--80.9% of cases of mood disorder, substance use disorder, or impulse control disorder.Table 6Comorbidity of SAD with other DSM-IV disordersSAD cases with comorbid disordersMood disorder^a^Anxiety disorder^b^Impulse control disorder^c^Substance use disorder^d^Any mental disorder^e^%SE%SE%SE%SE%SELifetime comorbidity^f^ Lifetime47.01.059.81.019.30.826.70.878.80.8 12-month49.81.264.91.221.91.127.01.081.81.012-month comorbidity^g^ 12-month33.41.152.71.212.70.910.20.766.91.2Temporal priority of SAD^h^ Lifetime71.81.135.41.249.82.380.91.340.41.1 12-month69.11.531.41.448.82.379.71.635.21.2^a^Respondents with major depressive episode or bipolar disorder (broad)^b^Respondents with panic disorder, generalized anxiety disorder, specific phobia, agoraphobia, post-traumatic stress disorder, or separation anxiety disorder^c^Respondents with intermittent explosive disorder, conduct disorder, attention deficit disorder, oppositional defiant disorder, binge eating disorder, or bulimia nervosa^d^Respondents with alcohol abuse with or without dependence or drug abuse with or without dependence^e^Respondents with any disorder listed above^f^Percentage of respondents with either lifetime or 12-month SAD who also meet lifetime criteria for at least one of the other DSM-IV disorders^g^The human services sector or complementary and alternative medicine (CAM) sector^h^Percentage of respondents with either lifetime or 12-month SAD and at least one of the other disorders, whose age of onset of SAD is reported to be younger than the age of onset of all comorbid disorders under consideration (i.e., either mood, anxiety, substance use, impulse control, or any disorder)*SE* standard error

Treatment {#Sec16}
---------

Among those with 12-month SAD, the percentage reporting treatment of any kind (i.e., specialty mental health, general medical care, health care, human services, complementary and alternative medicine, non-health care) in the past 12 months differs significantly by impairment, with 38% receiving any treatment (Table [7](#Tab7){ref-type="table"}). Across all countries, any treatment is lowest in those with moderate impairment (27.4%), and highest in those with severe impairment (46.9%). This pattern holds true for specialty mental health, general medical care, and health care, but human services, complementary and alternative medicine, and non-health care are most commonly used by those with mild impairment. Treatment rates for those with any impairment are lowest in low/lower-income countries (18.0%), and highest in high income countries (44.2%). This pattern holds true for cases with any impairment across all treatment sectors, and for almost all treatment sectors across different levels of impairment.Table 7Among those with 12-month SAD, percent reporting treatment in the past 12 months by Sheehan impairment severitySector of treatmentSheehan Disability Scale (SDS) category^a^Mild impairmentModerate impairmentSevere impairmentAny impairment(Score: 1--3)(Score: 4--6)(Score: 7--10)%SEComparison between countries^b^%SEComparison between countries^b^%SEComparison between countries^b^%SEComparison between countries^b^Specialty mental health^c^ Low/lower-middle income10.76.0χ^2^ = 1.4, *P* = 0.255.22.4χ^2^ = 3.4\*, *P* = 0.036.32.3χ^2^ = 33.4\*, *P* \< 0.0017.81.9χ^2^ = 32.6\*, *P* \< 0.001 Upper-middle income13.94.212.42.615.33.013.21.7 High income19.22.012.61.434.41.723.30.9 All countries combined17.51.711.71.127.71.419.80.8General medical^d^ Low/lower-middle income----χ^2^ = 14.4\*, *P* \< 0.0019.93.7χ^2^ = 5.1\*, *P* = 0.017.02.4χ^2^ = 44.8\*, *P* \< 0.0017.81.7χ^2^ = 65.6\*, *P* \< 0.001 Upper-middle income13.83.912.33.115.02.813.71.7 High income28.82.220.91.939.01.930.81.1 All countries combined23.91.817.81.531.01.525.20.9Health care^e^ Low/lower-middle income12.46.0χ^2^ = 8.6\*, *P* \< 0.00115.04.1χ^2^ = 3.3\*, *P* = 0.0412.73.2χ^2^ = 43.7\*, *P* \< 0.00114.52.6χ^2^ = 54.3\*, *P* \< 0.001 Upper-middle income23.64.622.63.426.03.623.71.9 High income36.72.326.72.054.61.940.91.1 All countries combined32.02.024.51.644.61.634.90.9Human services^f^ Low/lower-middle income----χ^2^ = 5.1\*, *P* = 0.01----χ^2^ = 0.3, *P* = 0.763.51.7χ^2^ = 5.1\*, *P* = 0.013.41.3χ^2^ = 2.5, *P* = 0.08 Upper-middle income4.52.44.82.02.31.23.61.1 High income7.71.63.50.87.11.05.70.5 All countries combined6.51.23.90.85.80.75.10.5CAM^g^ Low/lower-middle income----------χ^2^ = 14.3\*, *P* \< 0.001----χ^2^ = 12.5\*, *P* \< 0.0011.60.6χ^2^ = 26.9\*, *P* \< 0.001 Upper-middle income----2.71.42.51.22.30.7 High income9.11.75.20.98.51.07.80.6 All countries combined7.31.34.00.76.60.86.10.5Non-health care^h^ Low/lower-middle income----χ^2^ = 6.3\*, *P* \< 0.001----χ^2^ = 0.2, *P* = 0.804.71.8χ^2^ = 11.9\*, *P* \< 0.0014.51.4χ^2^ = 15.1\*, *P* \< 0.001 Upper-middle income5.02.47.32.34.71.75.61.3 High income13.71.97.61.113.61.311.70.7 All countries combined11.31.57.21.011.01.09.80.6Any treatment^i^ Low/lower-middle income15.96.1χ^2^ = 9.2\*, *P* \< 0.00120.24.9χ^2^ = 2.0, *P* = 0.1315.33.4χ^2^ = 44.5\*, *P* \< 0.00118.02.7χ^2^ = 52.3\*, *P* \< 0.001 Upper-middle income26.64.724.63.527.23.725.72.1 High income41.82.529.52.057.11.944.21.1 All countries combined36.62.127.41.746.91.638.01.0\*Significant at the 0.05 levelA dash was inserted for low cell counts (\<5 cases)^a^Highest severity category across four SDS role domains^b^Chi-square test of homogeneity to determine if there is variation in prevalence of treatment estimates across countries. Chi-square test is only generated where there is more than one stable cell (\> = 5 cases) for each combination of treatment sector and Sheehan impairment^c^The mental health specialist sector, which includes psychiatrist and non-psychiatrist mental health specialists (psychiatrist, psychologist, or other non-psychiatrist mental health professional; social worker or counselor in a mental health specialty setting; use of a mental health helpline; or overnight admissions for a mental health or drug or alcohol problems, with a presumption of daily contact with a psychiatrist)^d^The general medical sector (general practitioner, other medical doctor, nurse, occupational therapist, or any health care professional)^e^The mental health specialist sector or the general medical sector^f^The human services sector (religious or spiritual advisor or social worker or counselor in any setting other than a specialty mental health setting)^g^The CAM (complementary and alternative medicine) sector (any other type of healer such as herbalist or homeopath, participation in an Internet support group, or participation in a self-help group)^h^The human services sector or CAM^i^Respondents who sought any form of professional treatments listed in the footnotes above

Discussion {#Sec17}
==========

A number of limitations of the current study deserve mention. A first important issue is that of sampling. Response rates differ widely across the WMH surveys \[[@CR12]\]; while response rates do not appear to be related to SAD prevalence, it is possible that in some settings, particularly those where treatment is less available, those with the most severe SAD were unable to participate in surveys. Surveys also differed in their focus; some included only metropolitan areas, while others employed nationally representative samples; such differences may also have affected prevalence estimates. The surveys also excluded a range of respondents, including institutionalized patients, and people who were too intoxicated to be interviewed. Finally, samples in the WMH surveys also reflected survivor bias; given the 10- to 15-year gap in life expectancy between those in lower and higher income countries, this may also affect prevalence estimates \[[@CR23]\]. Taken together, the prevalence rates provided here are therefore conservative. It is also relevant to note that only two African countries were studied, limiting conclusions about distinctions across geographic regions.

Second, the measure of SAD used in the WMH surveys has important limitations. The CIDI relies on a screening section that employs relatively few stem questions, and this may lead to under-estimation of SAD in some settings (as noted, there is no stem question that addresses the symptom of offending others, which is thought to characterize social anxiety in some cultures, and which is now captured in the DSM-5 diagnostic criteria for SAD) \[[@CR24]--[@CR27]\]. Furthermore, no attempt was made to develop distinct cut-off points for SAD in different countries or to go beyond the DSM-IV criteria to develop distinct criteria for different countries that might have increased detection of SAD. It is relevant to emphasize that in countries where blinded clinical reappraisal interviews were undertaken, there was no evidence for systematic bias in the diagnostic threshold for SAD \[[@CR18]\]. However, clinical reappraisal interviews were carried out in only a subset of WMH countries, and it is possible that such studies would have found systematic differences in CIDI sensitivity and specificity across contexts.

Bearing in mind these limitations, the WMH surveys provide unique cross-national data on SAD, and are able to address a number of questions about this disorder. Some cross-national differences in SAD epidemiology are apparent: SAD 30-day, 12-month, and lifetime prevalence are lowest in low/lower-middle income countries and in the African and Eastern Mediterranean regions, highest in upper-middle income countries and the Americas and the Western Pacific regions, and there are some differences in domains of role impairment and in treatment rates across country, income region, and WHO region. Crucially, however, there are a number of consistent patterns across the globe: SAD has an early age of onset, is a persistent disorder, and is associated with specific socio-demographic features (younger age, female sex, unmarried status, lower education, and lower income) and with similar patterns of comorbidity and health care utilization.

A previous cross-national study indicated that SAD prevalence differs across different countries, with lifetime prevalence estimates ranging from 0.5 in Korea to 2.6 in the USA \[[@CR8]\]. However, that survey was done in only four countries, and assessed only three social fears as part of the simple phobia section of the Diagnostic Interview Schedule. The current data extend such work with surveys across a broad range of countries, and with a comprehensive assessment of SAD. Differences in prevalence across countries continue to be observed, as is the case for other common mental disorders in the WMH surveys. Such differences may reflect artifactual variation across surveys (for example, mental disorder stigma may be higher in lower income settings, resulting in decreased willingness to self-disclose, and an under-estimation of prevalence) or cross-national differences in underlying mechanisms relevant to pathogenesis (for example, greater access to greater social capital and more community engagement in lower income countries).

However, the finding here of similar proportions of SAD respondents with any severe role impairment across country income and geographic groupings suggests that differences in prevalence are not simply due to regional differences in diagnostic thresholding. In higher income countries and in particular regions of the globe such as the Americas, Western Pacific, and Western Europe, there is a higher prevalence of SAD, and SAD is associated with more impairment in the social domain than in other domains, suggesting high demands for social performance in such contexts. The persistence of SAD as well as proportion with any role impairment are highest in upper-middle income countries, Africa, and the Eastern Mediterranean, perhaps pointing to growing performance demands in these regions, but with fewer treatment resources than in higher income countries. The disjunction between lower prevalence but higher persistence of SAD in particular regions may be valuable in suggesting hypotheses, such as this one, about relevant causal mechanisms in SAD.

Our findings that SAD epidemiology demonstrates similar patterns across the globe, being associated with early age of onset, impairment in multiple domains, characteristic socio-demographic correlates (younger age, female gender, unmarried status, lower education, lower household income), and particular patterns of mental disorder comorbidity, again confirms and extends previous work. Thus, for example, we were able to demonstrate that across the globe SAD disorder persistence is particularly highly associated with lower education, episode persistence is particularly associated with being a student, while both disorder and episode persistence are associated with being a homemaker. While it has previously been demonstrated that SAD more likely follows other anxiety disorders, and precedes depression \[[@CR1]\], here we provide novel data on the comorbidity of SAD with impulse control disorders; this is valuable given that a link between social anxiety and aggression has been posited in the animal and clinical literature \[[@CR28], [@CR29]\]. It is notable that in both lifetime and 12-month SAD, SAD begins earlier in only 31.4--35.4% of cases of comorbid anxiety disorder, due to the common comorbidity with specific phobia which has the earliest onset of the anxiety disorders, but SAD begins earlier in 48.8--80.9% of cases of comorbid mood disorder, substance use disorder, or impulse control disorder. We also provide novel data on treatment rates; these are highest where impairment is most severe and in countries with higher income.

Conclusions {#Sec18}
===========

In conclusion, data from the WMH survey provide the most comprehensive picture of the global epidemiology of SAD to date and help address the key question of whether this condition is a peculiarly Western construct. There are apparent differences in SAD prevalence and domains of role impairment across the globe, with further work needed to delineate more rigorously the reasons for such differences and to investigate possible mechanisms relevant to understanding them. Nevertheless, the data indicate that across the world, SAD is a prevalent condition that is characterized by early age of onset, as well as disorder and episode persistence. Furthermore in low, middle, and high income countries, as well as in a range of geographic regions, SAD is associated with specific socio-demographic correlates (younger age, female gender, unmarried status, lower education, lower household income), particular comorbidity patterns (typically beginning later than specific phobia, but earlier than other anxiety disorders, mood, substance use, or impulse control disorders), and common patterns of health care utilization. Taken together, these cross-national data emphasize the international clinical and public health significance of SAD.

Appendix 1 {#Sec19}
==========

Table 8Days out of role due to 12-month SAD by role impairmentSheehan disability domainDays out of role due to 12-month social anxiety phobia^b^Severe (Score: 7-10)Not severe (Score: 0-6)*F* test, *P* value^c^Number (*n*)MeanSENumber (*n*)MeanSEHome201012.81.235592.68.875.9\*, *P* \< 0.001Work18048.40.953684.06.9116.6\*, *P* \< 0.001Relationship162911.41.574354.24.767.5\*, *P* \< 0.001Social14729.41.390149.84.182.6\*, *P* \< 0.001Any^a^11834.50.7119345.43.5124.3\*, *P* \< 0.001\*Significant at the 0.05 level^a^Mean days out of role presented for subgroups of respondents defined by their highest severity category across the four Sheehan disability domains (home, work, relationship, and social)^b^Mean (SE) days out of role due to 12-month SAD: 24.7 (1.8) days^c^Bivariate linear regression to test for significant differences in severity. No controls were used

Appendix 2 {#Sec20}
==========

Table 9Bivariate associations between socio-demographics correlates and DSM-IV SAD (low/lower-middle income countries)Correlates30-day SAD^a^Lifetime SAD^b^12-month SAD among lifetime cases^c^30-day SAD among 12-month cases^c^OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)Age-cohort 18--296.7\*(2.9--15.5)7.1\*(4.3--11.6) 30--444.8\*(2.1--11.0)4.7\*(2.8--7.7) 45--593.6\*(1.4--8.9)3.2\*(1.9--5.5) 60+1.01.0Age-cohort difference^d^χ^2^ ~3~ = 26.6\*, *P* \< 0.001χ^2^ ~3~ = 74.7\*, *P* \< 0.001Age of onset Early2.7\*(1.3--5.5)1.3(0.6--2.8) Early-average1.4(0.8--2.4)1.4(0.7--3.2) Late-average1.1(0.6--1.9)1.4(0.7--2.8) Late1.01.0Age of onset difference^d^χ^2^ ~3~ = 9.3\*, *P* = 0.026χ^2^ ~3~ = 1.3, *P* = 0.721Time since onset (continuous)0.98\*(0.96--0.99)0.99(0.97--1.02)χ^2^ ~1~ = 7.4\*, *P* = 0.007χ^2^ ~1~ = 0.3, *P* = 0.573Gender Female1.4(0.9--2.1)1.1(0.9--1.4)1.5(1.0--2.2)1.1(0.7--1.9) Male1.01.01.01.0Gender difference^d^χ^2^ ~1~ = 2.8, *P* = 0.092χ^2^ ~1~ = 1.3, *P* = 0.255χ^2^ ~1~ = 3.7, *P* = 0.055χ^2^ ~1~ = 0.2, *P* = 0.679Employment status Student1.4(0.6--3.1)1.1(0.6--1.8)1.7(0.6--4.8)3.7\*(1.3--10.8) Homemaker1.4(0.8--2.4)1.0(0.8--1.4)1.7(0.9--3.2)1.3(0.6--3.0) Retired0.7(0.3--1.9)1.9(1.0--3.8)0.6(0.2--1.5)0.7(0.3--2.2) Other1.0(0.6--1.7)1.0(0.7--1.3)2.4\*(1.2--4.9)0.8(0.4--1.7) Employed1.01.01.01.0Employment status difference^d^χ^2^ ~4~ = 2.7, *P* = 0.606χ^2^ ~4~ = 4.2, *P* = 0.387χ^2^ ~4~ = 9.9\*, *P* = 0.043χ^2^ ~4~ = 7.4, *P* = 0.115Marital status Never married1.1(0.7--1.7)1.4\*(1.1--1.8)0.8(0.5--1.3)1.0(0.5--1.8) Divorced/separated/widowed1.3(0.8--2.1)1.3(0.9--1.8)1.0(0.5--2.1)1.2(0.5--2.7) Currently married1.01.01.01.0Marital status difference^d^χ^2^ ~2~ = 0.8, *P* = 0.664χ^2^ ~2~ = 7.4\*, *P* = 0.025χ^2^ ~2~ = 1.0, *P* = 0.613χ^2^ ~2~ = 0.2, *P* = 0.927Education level No education1.2(0.4--3.1)0.9(0.5--1.8)----1.1(0.3--3.6) Some primary1.4(0.6--3.2)0.9(0.5--1.4)1.5(0.6--4.2)2.8(0.9--8.9) Primary finished1.9(0.8--4.1)1.1(0.7--1.8)1.6(0.7--3.7)2.0(0.7--6.2) Some secondary1.2(0.5--2.5)0.9(0.6--1.3)1.5(0.7--3.3)1.0(0.5--2.4) Secondary finished0.9(0.5--1.7)1.0(0.7--1.4)1.5(0.8--2.9)0.8(0.4--1.6) Some college0.6(0.3--1.0)0.8(0.6--1.2)1.1(0.5--2.1)0.5(0.2--1.3) College finished1.01.01.01.0Education level difference^d^χ^2^ ~3~ = 12.2, *P* = 0.058χ^2^ ~3~ = 2.6, *P* = 0.856χ^2^ ~3~ = 3.5, *P* = 0.739χ^2^ ~3~ = 8.9, *P* = 0.181Household income Low0.9(0.5--1.6)0.9(0.6--1.2)1.2(0.6--2.3)1.2(0.6--2.6) Low-average1.2(0.6--2.1)0.9(0.7--1.3)2.0\*(1.0--4.1)0.9(0.4--2.1) High-average0.9(0.5--1.5)0.9(0.7--1.2)1.8(0.9--3.6)0.7(0.4--1.4) High1.01.01.01.0Household income difference^d^χ^2^ ~3~ = 1.4, *P* = 0.709χ^2^ ~3~ = 1.0, *P* = 0.800χ^2^ ~3~ = 5.9, *P* = 0.117χ^2^ ~3~ = 2.4, *P* = 0.498*N* ^e^36,4981,426,232564349\*Significant at the 0.05 level, two-sided test^a^These estimates are based on logistic regression models adjusted for age, gender, and low/lower-middle income countries^b^These estimates are based on survival models adjusted for age-cohorts, gender, person-years, and low/lower-middle income countries^c^These estimates are based on logistic regression models adjusted for time since SAD onset, age of SAD onset, gender, and low/lower-middle income countries^d^Chi-square test exploring significant differences between blocks of socio-demographic variables^e^Denominator *N*: 36,498 = total sample; 1,426,232 = number of person-years in the survival model; 564 = number of lifetime cases of SAD; 349 = number of 12-month cases of SADA dash was inserted for low cell counts (\<5 cases)
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Table 10Bivariate associations between socio-demographics correlates and DSM-IV SAD (upper-middle income countries)Correlates30-day SAD^a^Lifetime risk of SAD^b^12-month SAD among lifetime cases^c^30-day SAD among 12-month cases^c^OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)Age-cohort 18--292.0\*(1.2--3.1)3.9\*(2.7--5.5) 30--442.1\*(1.3--3.3)2.9\*(2.1--4.0) 45--591.9\*(1.2--3.1)2.1\*(1.5--3.1) 60+1.01.0Age-cohort difference^d^χ^2^ ~3~ = 9.8\*, *P* = 0.021χ^2^ ~3~ = 70.3\*, *P* \< 0.001Age of onset Early1.0(0.6--2.0)0.5\*(0.3--1.0) Early-average0.8(0.5--1.4)0.6(0.3--1.1) Late-average0.9(0.5--1.5)1.0(0.6--1.7) Late1.01.0Age of onset difference^d^χ^2^ ~3~ = 1.0, *P* = 0.810χ^2^ ~3~ = 6.4, *P* = 0.092Time since onset (continuous)0.99(0.98--1.01)1.02\*(1.00--1.03)χ^2^ ~1~ = 1.0, *P* = 0.309χ^2^ ~1~ = 5.8\*, *P* = 0.016Gender Female2.0\*(1.6--2.6)1.5\*(1.3--1.8)1.6\*(1.1--2.4)1.6\*(1.0--2.3) Male1.01.01.01.0Gender difference^d^χ^2^ ~1~ = 29.5\*, *P* \< 0.001χ^2^ ~1~ = 19.6\*, *P* \< 0.001χ^2^ ~1~ = 4.7\*, *P* = 0.030χ^2^ ~1~ = 4.5\*, *P* = 0.034Employment status Student1.8(1.0--3.3)1.4(0.9--2.1)0.6(0.3--1.5)---- Homemaker1.3(1.0--1.8)1.1(0.8--1.3)1.4(0.8--2.3)1.8\*(1.1--3.1) Retired0.4\*(0.2--0.9)0.7(0.5--1.0)1.0(0.4--2.7)0.4(0.1--1.3) Other1.4(1.0--2.0)1.3(1.0--1.6)1.0(0.6--1.8)1.2(0.7--2.1) Employed1.01.01.01.0Employment status difference^d^χ^2^ ~4~ = 15.8\*, *P* = 0.003χ^2^ ~4~ = 7.8, *P* = 0.101χ^2^ ~4~ = 3.9, *P* = 0.414χ^2^ ~4~ = 18.7\*, *P* = 0.001Marital status Never married1.0(0.7--1.3)1.3\*(1.0--1.7)1.0(0.6--1.6)0.8(0.5--1.2) Divorced/separated/widowed1.1(0.8--1.6)1.3\*(1.0--1.7)1.0(0.6--1.7)0.8(0.4--1.4) Currently married1.01.01.01.0Marital status difference^d^χ^2^ ~2~ = 0.4, *P* = 0.815χ^2^ ~2~ = 8.4\*, *P* = 0.015χ^2^ ~2~ = 0.0, *P* = 0.996χ^2^ ~2~ = 1.5, *P* = 0.484Education level No education1.4(0.7--2.9)0.7(0.4--1.2)----2.1(0.6--7.4) Some primary1.7\*(1.1--2.8)0.9(0.7--1.3)3.8\*(2.0--7.3)2.2(0.9--5.3) Primary finished1.6(1.0--2.6)1.1(0.8--1.6)2.4\*(1.1--5.1)1.3(0.5--3.3) Some secondary1.4(0.9--2.2)1.2(0.9--1.6)1.3(0.7--2.6)1.2(0.6--2.4) Secondary finished1.0(0.6--1.6)0.9(0.7--1.2)1.1(0.6--2.0)1.4(0.7--2.7) Some college1.0(0.6--1.7)1.1(0.8--1.5)1.5(0.6--3.8)0.7(0.3--1.6) College finished1.01.01.01.0Education level difference^d^χ^2^ ~3~ = 12.9\*, *P* = 0.044χ^2^ ~3~ = 10.6, *P* = 0.102χ^2^ ~3~ = 37.1\*, *P* \< 0.001χ^2^ ~3~ = 9.3, *P* = 0.157Household income Low1.2(0.8--1.7)1.0(0.8--1.2)0.9(0.5--1.6)1.6(0.8--3.1) Low-average1.2(0.8--1.8)1.0(0.8--1.3)1.2(0.7--2.0)1.6(0.9--2.8) High-average1.2(0.9--1.6)0.8(0.7--1.1)1.3(0.7--2.3)2.0\*(1.2--3.5) High1.01.01.01.0Household income difference^d^χ^2^ ~3~ = 1.7, *P* = 0.649χ^2^ ~3~ = 3.1, *P* = 0.384χ^2^ ~3~ = 2.0, *P* = 0.580χ^2^ ~3~ = 6.7, *P* = 0.082*N* ^e^28,9271,206,689834601\*Significant at the 0.05 level, two-sided test^a^These estimates are based on logistic regression models adjusted for age, gender, and upper-middle income countries^b^These estimates are based on survival models adjusted for age-cohorts, gender, person-years, and upper-middle income countries^c^These estimates are based on logistic regression models adjusted for time since SAD onset, age of SAD onset, gender, and upper-middle income countries^d^Chi-square test exploring significant differences between blocks of socio-demographic variables^e^Denominator *N*: 28,927 = total sample; 1,206,689 = number of person-years in the survival model; 834 = number of lifetime cases of SAD; 601 = number of 12-month cases of SADA dash was inserted for low cell counts (\<5 cases)
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Table 11Bivariate associations between socio-demographics correlates and DSM-IV SAD (high income countries)Correlates30-day SAD^a^Lifetime SAD^b^12-month SAD among lifetime cases^c^30-day SAD among 12-month cases^c^OR(95% CI)OR(95% CI)OR(95% CI)OR(95% CI)Age-cohort 18--293.3\*(2.7--4.2)3.3\*(3.0--3.8) 30--442.8\*(2.3--3.5)2.8\*(2.5--3.2) 45--592.5\*(2.0--3.2)2.3\*(2.1--2.7) 60+1.01.0Age-cohort difference^d^χ^2^ ~3~ = 119.5\*, *P* \< 0.001χ^2^ ~3~ = 414.6\*, *P* \< 0.001Age of onset Early1.5\*(1.1--1.9)1.0(0.8--1.4) Early-average1.5\*(1.2--1.9)0.9(0.7--1.3) Late-average1.2(0.9--1.4)0.9(0.7--1.1) Late1.01.0Age of onset difference^d^χ^2^ ~3~ = 13.4\*, *P* = 0.004χ^2^ ~3~ = 1.8, *P* = 0.615Time since onset (Continuous)0.98\*(0.97--0.98)1.01(1.00--1.01)χ^2^ ~1~ = 57.0\*, *P* \< 0.001χ^2^ ~1~ = 2.9, *P* = 0.087Gender Female1.6\*(1.4--1.8)1.3\*(1.2--1.4)1.3\*(1.1--1.5)1.2(1.0--1.4) Male1.01.01.01.0Gender difference^d^χ^2^ ~1~ = 38.8\*, *P* \< 0.001χ^2^ ~1~ = 44.7\*, *P* \< 0.001χ^2^ ~1~ = 8.5\*, *P* = 0.004χ^2^ ~1~ = 2.8, *P* = 0.097Employment status Student1.3(1.0--1.8)1.1(0.9--1.4)1.2(0.8--1.8)1.5(1.0--2.3) Homemaker1.4\*(1.2--1.8)1.2\*(1.1--1.4)1.3\*(1.0--1.7)1.3(0.9--1.8) Retired0.7\*(0.5--1.0)0.8\*(0.7--1.0)1.1(0.8--1.5)1.1(0.7--1.6) Other2.2\*(1.8--2.7)1.6\*(1.5--1.9)2.3\*(1.7--3.1)1.0(0.7--1.4) Employed1.01.01.01.0Employment status difference^d^χ^2^ ~4~ = 81.7\*, *P* \< 0.001χ^2^ ~4~ = 84.1\*, *P* \< 0.001χ^2^ ~4~ = 34.4\*, *P* \< 0.001χ^2^ ~4~ = 5.3, *P* = 0.258Marital status Never married1.3\*(1.1--1.6)1.4\*(1.3--1.6)1.5\*(1.2--1.8)1.0(0.8--1.3) Divorced/separated/widowed1.6\*(1.3--2.0)1.3\*(1.2--1.5)1.5\*(1.2--1.8)1.1(0.9--1.4) Currently married1.01.01.01.0Marital status difference^d^χ^2^ ~2~ = 30.0\*, *P* \< 0.001χ^2^ ~2~ = 63.3\*, *P* \< 0.001χ^2^ ~2~ = 26.0\*, *P* \< 0.001χ^2^ ~2~ = 0.7, *P* = 0.709Education level No education---------------- Some primary1.9\*(1.1--3.1)1.2(1.0--1.6)2.9\*(1.7--5.0)1.5(0.7--3.1) Primary finished1.3(0.8--1.9)1.2(1.0--1.5)1.7\*(1.0--2.9)0.9(0.5--1.5) Some secondary1.4\*(1.1--1.8)1.2\*(1.1--1.4)1.7\*(1.3--2.1)1.0(0.7--1.4) Secondary finished1.0(0.8--1.2)1.1(1.0--1.2)1.3\*(1.1--1.6)0.8(0.6--1.0) Some college1.1(0.9--1.4)1.2\*(1.0--1.3)1.3\*(1.0--1.7)0.8(0.6--1.1) College finished1.01.01.01.0Education level difference^d^χ^2^ ~3~ = 17.2\*, *P* = 0.009χ^2^ ~3~ = 15.6\*, *P* = 0.016χ^2^ ~3~ = 29.4\*, *P* \< 0.001χ^2^ ~3~ = 7.6, *P* = 0.268Household income Low1.6\*(1.3--2.0)1.2\*(1.1--1.4)1.8\*(1.4--2.2)1.3(1.0--1.8) Low-average1.3\*(1.0--1.6)1.0(0.9--1.2)1.4\*(1.1--1.7)1.3(1.0--1.8) High-average1.1(0.9--1.4)1.1(1.0--1.2)1.1(0.9--1.4)1.0(0.8--1.4) High1.01.01.01.0Household income difference^d^χ^2^ ~3~ = 25.1\*, *P* \< 0.001χ^2^ ~3~ = 15.9\*, *P* = 0.001χ^2^ ~3~ = 32.7\*, *P* \< 0.001χ^2^ ~3~ = 5.7, *P* = 0.126*N* ^e^76,9803,448,64043602510\*Significant at the 0.05 level, two-sided test^a^These estimates are based on logistic regression models adjusted for age, gender, and high income countries^b^These estimates are based on survival models adjusted for age-cohorts, gender, person-years, and high income countries^c^These estimates are based on logistic regression models adjusted for time since SAD onset, age of SAD onset, gender, and high income countries^d^Chi-square test exploring significant differences between blocks of socio-demographic variables^e^Denominator *N*: 76,980 = total sample; 3,448,640 = number of person-years in the survival model; 4360 = number of lifetime cases of SAD; 2510 = number of 12-month cases of SADA dash was inserted for low cell counts (\<5 cases)
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